The key considerations in the design of VBI-1901 are (1) boost both CD4 + (CMV gB) and CD8 + (CMV pp65) T-cell responses, (2) elicit a broadly reactive T-cell repertoire against multiple epitopes to avoid rapid tumor immunoselection/escape, and (3) have a potent delivery system where enveloped virus-like particles (eVLPs) expressing the CMV gB and pp65 antigens are formulated with granulocyte–macrophage colony-stimulating factor and given intradermally. Here, CD8A is linked to neoplasm.